Intravitreal Adalimumab for the Control of Breakthrough Intraocular Inflammation

Abstract

Intravitreal adalimumab warrants further investigation as a potentially effective, practical and safe adjunctive therapy for the control of breakthrough inflammation in select patients maintained on systemic adalimumab.